République Tunisienne  
Ministère de l'Agriculture, des Ressources Hydrauliques et de la Pêche

Connexion

Connexion

exploiting-serological-data-to-understand-the-epidemiology-of-bluetongue-virus-serotypes-circulating-in-libya

Exploiting serological data to understand the epidemiology of bluetongue virus serotypes circulating in Libya>   Description

 
Date de publication 2018
Télécharger

Exploiting serological data to understand the epidemiology of bluetongue virus serotypes circulating in Libya

Auteur  A. S. Mahmoud, G. Savini, M. Spedicato, F. Monaco, I. Carmine, A. Lorusso, T. Francesco, M. Mazzei, M. Forzan, I. Eldaghayes et A. Dayhum
Mots clés

 BT, Novel BTV serotypes, BTV-3, BTV-26, Sero-prevalence, Libya

Résumé

The epidemiological patterns of Bluetongue (BT) in North Africa and Mediterranean Basin (MB) dramatically changed by emergence of subsequent episodes of novel bluetongue virus (BTV) serotypes with highly pathogenic indexes and socio-economic impacts. The objective of the study was to investigate the sero-prevalence and serotype distribution of BTV in Libya. During 2015-2016, a total of 826 serum samples were collected from domestic ruminants in Libya. All sera were assayed by competitive enzyme-linked immunosorbent assays (c-ELISA). C-Elisa-positive samples (43.3%; 173/400) were further analyzed by virus neutralization assay to identify BTV serotypes and determine the antibody titre of positive samples. An overall BTV sero-prevalence was 48.4% (95% CI: 45.0%-51.8%). Neutralizing antibodies were detected against the following BTV serotypes namely: BTV-1, BTV-2, BTV-3, BTV-4, BTV-9 and BTV-26. While BTV-1, BTV-2, BTV-4 and BTV-9 circulation was unsurprising as they have been responsible of the last year outbreaks in Northern African Countries, the detection of BTV-3 and BTV-26 was definitely new and concerning for the animal health of the countries facing the Mediterranean Basin. It is crucial that European and Northern African authorities collaborate in organizing common surveillance programmes to early detect novel strains or emerging serotypes in order to set up proper preventive measures, and, in case, develop specific vaccines and plan coordinated
vaccination campaigns.

Lu 1392 fois Dernière modification le lundi, 07 janvier 2019 17:10